[Pneumocystis jiroveci: epidemiological, pathophysiological and biological update].
One century after its discovery, Pneumocystis jiroveci is an infectious agent still responsible of a high mortality rate among immunocompromised patients. Molecular biology advances have authorized some important progress mainly concerning epidemiology, pathophysiology and biological diagnosis. It has also brought a lot of publication on the subject. They describe a large panel of different biological diagnosis method. The purpose of this article is to synthesize these knowledges and to update the laboratory diagnosis strategy.
Vedy
S
S
Fédération des laboratoires, Hôpital d'instruction des armées Legouest, Metz Armées. vedy.serge@wanadoo.fr
Ragot
C
C
Robet
Y
Y
Puyhardy
J-M
JM
D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D006801:Humans; D016867:Immunocompromised Host; D016720:Pneumocystis Infections / Q000453:epidemiology* / Q000276:immunology / Q000503:physiopathology; D045363:Pneumocystis carinii / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome